# Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer

> **NCT00002950** · PHASE1,PHASE2 · COMPLETED · sponsor: **Yale University** · enrollment: 25 (estimated)

## Conditions studied

- Unspecified Adult Solid Tumor, Protocol Specific

## Interventions

- **BIOLOGICAL:** sargramostim
- **DRUG:** topotecan hydrochloride

## Key facts

- **NCT ID:** NCT00002950
- **Lead sponsor:** Yale University
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1996-09-26
- **Primary completion:** 2002-02-10
- **Final completion:** 2002-02-10
- **Target enrollment:** 25 (ESTIMATED)
- **Last updated:** 2020-08-17

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00002950

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00002950, "Topotecan Plus Sargramostim in Treating Patients With Advanced Cancer". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00002950. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*